CDC5L
Basic information
Region (hg38): 6:44387706-44450425
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CDC5L gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 11 | |||||
missense | 24 | 28 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 2 | 3 | |||
non coding | 18 | 21 | ||||
Total | 0 | 0 | 24 | 11 | 25 |
Variants in CDC5L
This is a list of pathogenic ClinVar variants found in the CDC5L region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-44387817-C-T | CDC5L-related disorder | Likely benign (Apr 12, 2019) | ||
6-44387822-A-G | CDC5L-related disorder | Likely benign (Aug 18, 2023) | ||
6-44387945-G-A | Benign (Nov 10, 2018) | |||
6-44387962-T-C | Benign (Nov 10, 2018) | |||
6-44390147-T-G | Benign (Jun 18, 2021) | |||
6-44390288-G-A | CDC5L-related disorder | Likely benign (Jun 04, 2019) | ||
6-44390369-A-G | CDC5L-related disorder | Uncertain significance (May 29, 2024) | ||
6-44390707-T-G | Benign (Nov 10, 2018) | |||
6-44392418-T-A | Benign (Jun 18, 2021) | |||
6-44392728-C-G | not specified | Uncertain significance (Jul 30, 2024) | ||
6-44392754-A-G | CDC5L-related disorder | Likely benign (Mar 05, 2021) | ||
6-44392796-G-A | Benign (Jun 09, 2021) | |||
6-44392943-A-G | Benign (Nov 10, 2018) | |||
6-44393530-A-G | CDC5L-related disorder | Likely benign (Mar 08, 2024) | ||
6-44393558-A-G | not specified | Uncertain significance (Jan 20, 2023) | ||
6-44393572-G-A | Benign (Aug 01, 2023) | |||
6-44396346-C-T | not specified | Uncertain significance (Jul 26, 2021) | ||
6-44396427-T-C | CDC5L-related disorder | Likely benign (Nov 26, 2019) | ||
6-44403855-A-T | not specified | Uncertain significance (Mar 27, 2023) | ||
6-44403874-G-A | not specified | Uncertain significance (Aug 09, 2021) | ||
6-44403874-G-C | not specified | Uncertain significance (Nov 03, 2022) | ||
6-44403919-A-C | not specified | Uncertain significance (Feb 07, 2023) | ||
6-44403967-A-G | Uncertain significance (Feb 26, 2018) | |||
6-44403977-C-T | Benign (Nov 10, 2018) | |||
6-44403982-A-G | not specified | Uncertain significance (Nov 21, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CDC5L | protein_coding | protein_coding | ENST00000371477 | 16 | 62902 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 5.68e-7 | 125697 | 0 | 6 | 125703 | 0.0000239 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.78 | 268 | 430 | 0.623 | 0.0000227 | 5267 |
Missense in Polyphen | 32 | 126.88 | 0.25221 | 1543 | ||
Synonymous | -0.729 | 158 | 147 | 1.08 | 0.00000752 | 1487 |
Loss of Function | 6.21 | 2 | 48.8 | 0.0410 | 0.00000302 | 548 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000116 | 0.000116 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000464 | 0.0000462 |
European (Non-Finnish) | 0.00000887 | 0.00000879 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: DNA-binding protein involved in cell cycle control. May act as a transcription activator. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. The PRP19-CDC5L complex may also play a role in the response to DNA damage (DDR). {ECO:0000269|PubMed:10570151, ECO:0000269|PubMed:11082045, ECO:0000269|PubMed:11101529, ECO:0000269|PubMed:11544257, ECO:0000269|PubMed:12927788, ECO:0000269|PubMed:18583928, ECO:0000269|PubMed:24332808, ECO:0000269|PubMed:9038199, ECO:0000269|PubMed:9468527, ECO:0000269|PubMed:9632794}.;
- Disease
- DISEASE: Note=A chromosomal aberration involving CDC5L is found in multicystic renal dysplasia. Translocation t(6;19)(p21;q13.1) with USF2.;
- Pathway
- Spliceosome - Homo sapiens (human);Metabolism of RNA;mRNA Splicing - Major Pathway;mRNA Splicing;Processing of Capped Intron-Containing Pre-mRNA
(Consensus)
Recessive Scores
- pRec
- 0.160
Intolerance Scores
- loftool
- 0.132
- rvis_EVS
- -0.8
- rvis_percentile_EVS
- 12.46
Haploinsufficiency Scores
- pHI
- 0.822
- hipred
- Y
- hipred_score
- 0.827
- ghis
- 0.662
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.975
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cdc5l
- Phenotype
Gene ontology
- Biological process
- mitotic cell cycle;mRNA splicing, via spliceosome;DNA repair;cellular response to fibroblast growth factor stimulus;positive regulation of transcription by RNA polymerase II;cellular response to interleukin-2;signal transduction involved in DNA damage checkpoint;cellular response to wortmannin;cellular response to nerve growth factor stimulus;cellular response to prolactin
- Cellular component
- Prp19 complex;nucleus;nucleoplasm;DNA replication factor A complex;cytoplasm;membrane;nuclear speck;perinuclear region of cytoplasm;U2-type catalytic step 2 spliceosome;catalytic step 2 spliceosome
- Molecular function
- RNA polymerase II regulatory region sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;transcription corepressor binding;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;RNA binding;protein binding;protein phosphatase 1 binding;protein kinase binding;leucine zipper domain binding;WD40-repeat domain binding